Viral oncolytic immunotherapy in the war on cancer: Infection control considerations

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

(2018) Jason Chesney et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma

(2018) Jason Chesney et al.   MELANOMA RESEARCH

Recurrent Glioblastoma Treated with Recombinant Poliovirus

(2018) Annick Desjardins et al.   NEW ENGLAND JOURNAL OF MEDICINE

Talimogene laherparepvec: First in class oncolytic virotherapy

(2018) Robert M. Conry et al.   Human Vaccines & Immunotherapeutics

The Next Phase of Human Gene-Therapy Oversight

(2018) Francis S. Collins et al.   NEW ENGLAND JOURNAL OF MEDICINE

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

(2016) Igor Puzanov et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy

(2015) F. J. Kohlhapp et al.   CLINICAL CANCER RESEARCH

Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1–derived oncolytic immunotherapy

(2015) Kevin J Harrington et al.   Expert Review of Anticancer Therapy

Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma

(2015) Douglas B Johnson et al.   Immunotherapy

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

First oncolytic virus edges towards approval in surprise vote

(2015) Cormac Sheridan   NATURE BIOTECHNOLOGY

OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma

(2010) Howard L Kaufman et al.   Future Oncology

Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

(2009) Neil N. Senzer et al.   JOURNAL OF CLINICAL ONCOLOGY